WEKO3
アイテム
Effective oral formulation of semaglutide (Rybelsus) for diabetes and obesity due to absorption enhancer development
https://tokushima-u.repo.nii.ac.jp/records/2009635
https://tokushima-u.repo.nii.ac.jp/records/200963509192ca7-7d40-491a-82e3-4738740bb759
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
ijed_5_1_130.pdf (162 KB)
|
.png)
|
| Item type | 文献 / Documents(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2022-02-15 | |||||
| アクセス権 | ||||||
| アクセス権 | open access | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| 出版社版DOI | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | https://doi.org/10.36266/IJED/130 | |||||
| 言語 | ja | |||||
| 関連名称 | 10.36266/IJED/130 | |||||
| 出版タイプ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
| タイトル | ||||||
| タイトル | Effective oral formulation of semaglutide (Rybelsus) for diabetes and obesity due to absorption enhancer development | |||||
| 言語 | en | |||||
| 著者 |
板東, 浩
× 板東, 浩 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Glucagon-Like Peptide 1 receptor agonist (GLP-1RA) have been recently effective for diabetes. Among them, subcutaneous injection and oral form of semaglutide (Rybelsus) are in focus, in which the latter has been examined in the Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) studies. Rybelsus could been invented for absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, due to 30-year process of innovation by Novo Nordisk. It shows clinical effects for diabetes and obesity. For PIONEER 9 and 10 trials, efficacy and safety were shown for 3, 7 or 14 mg of Rybelsus equivalent to subcutaneous liraglutide and subcutaneous dulaglutide for 52 weeks. | |||||
| 言語 | en | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | semaglutide | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Rybelsus | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Novo Nordisk | |||||
| 書誌情報 |
en : International Journal of Endocrinology and Diabetes 巻 5, 号 1, p. 130, 発行日 2022-01-28 |
|||||
| 収録物ID | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 26943875 | |||||
| 出版者 | ||||||
| 出版者 | Pubtexto Publishers | |||||
| 言語 | en | |||||
| 権利情報 | ||||||
| 言語 | en | |||||
| 権利情報 | This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | |||||
| 言語 | ||||||
| 言語 | eng | |||||
